Single fluconazole 150 mg oral capsule in vaginal candidiasis

Thirty four non-pregnant females between the ages of 23 and 45 years with a mean of 31.03 years and suffering from vaginal candidiasis were included in this study. The diagnosis was confirmed both clinically and mycologically by microscopy and culture. All patients received one capsule of Fluconazole 150mg orally and were seen 7-14 days after therapy as well as 30-45 days post-treatment. Complete cure with disappearance of all pretreatment signs and symptoms occurred in 30 patients [88 percent] while improvement occurred in 4 patients [12 percent]. Mycological cure with complete eradication of Candida was achieved in 31 patients [91 percent] while persistence was reported in 3 patients [9 percent]. No relapses were reported till the last follow up visit [day 30-45]. No statistically significant change in the mean values for blood picture, liver and renal function tests after therapy when compared to pretreatment figures. No adverse effects were reported in any of the included cases. This study concludes that oral Fluconazole in a single 150mg capsule is effective, safe and well tolerated for the treatment of vaginal candidiasis

Single oral dose fluconazole therapy in vaginal candidiasis

Fluconazole in a single oral 150 mg capsule was used to treat thirty adult non pregnant women proved to have positive vaginal cultures for candidiasis. Pruritus, discharge, and burning were the monitoring symptoms of the efficacy of therapy. Patients were seen at 3 visits; visit 1 before treatment, visit 2 [7-14 days after treatment] and visit 3 [30-45 days after treatment]. Criteria of cure were based on clinical and mycological results. At visit 2, pruritus and burning remained only in 3 and 2 patients respectively, while discharge was present in 9 cases showed positive vaginal culture [only 5 of them were symptomatic]. These five symptomatic cases, repeated the same treatment. 4 of them showed negative culture during the third visit one remains positive. Clinical tolerability to Fluconazole therapy was excellent in 29 cases while on case complained of transient vomiting. No significant were induced on blood picture, liver and renal function tests after therapy

prophylactic and therapeutic use of oral sultamicillin [sulbactam/ampicillin] in children with bacterial urinary tract infections

Thirty five children suffering from urinary tract infections [U.T.I.] [15 with acute and 20 with chronic recurrent U.T.I.] were included in the study. In vitro sensitivity to the drug showed 100% sensitivity in the acute cases and 75% in the chronic cases. The sensitive cases were treated with oral sultamicillin; a sulbactam-ampicillin combination. Excellent results were reported in fifteen cases with acute U.T.I. with complete disappearance of clinical signs and symptoms together with eradication of the causative organisms. Fifteen cases with chronic recurrent infections were divided into 2 groups. Six cases received the same dosage regimen used in acute U.T.I. After a short time from stopping therapy, superinfection occurred in one case. Nine cases with chronic recurrent U.T.I. were maintained on subtherapeutic therapy for up to 3 months with persistent eradication of causative organisms confirmed by follow up cultures. All patients showed excellent tolerability without appearance of any side effects. The study confirms the efficiency and tolerability of the drug in cases with acute U.T.I. and chronic or recurrent U.T.I. In the latter group, it should be only used if culture results proved its sensitivity. Maintenance with subtherapeutic dose is again recommended for prophylaxis

Intramuscular sulbactam/ampicillin combination therapy in gynecological and obstetrical bacterial infections

Clinical and bacteriological assessment of efficacy of intramuscular sulbactam / ampicillin combination, together with assessment of its toleration and safety in the treatment of gynecological and obstetrical infections were carried out thirty adult females with pelvic inflammatory disease, wound infections, vaginitis and puerperal sepsis received intramuscular sulbactam / ampicillin combination in a total daily dose of 1.5 gm. The duration of therapy ranged between 3 and 7 days. Clinical cure and improvement were achieved in 27 cases [90%] and no response was seen in 3 cases [10%]. No side effects were seen in 29 cases [96.7%], while tolerable local injection site pain was reported in 1 case. The safety of the sulbactam / ampicillin antibiotic combination was quite evident in all the studied cases through the absence of significant differences in the means of laboratory tests done before and after therapy on haemogram and renal functions

Sulbactam-ampicillin combination in the treatment of lower respiratory tract infections

Sulbactam is a beta-lactamase inhibitor, which by itself, has a little antibiotic activity but it extends the therapeutic range of ampicillin when combined with it. The combination is active against ampicillin resistant staphylococcus aureus, haemophilus influenzae, and organisms which are secretor of beta-lactamase enzyme including many other organisms. Thirty adult patients suffering from lower respiratory tract bacterial infections were treated with intramuscular sulbactam-ampicillin combination. Good to excellent clinical responses were achieved in all cases with eradication of 97.87% of causative organisms. The combination was well tolerated and neither local nor systemic side effects were observed. Follow up of haemobiochemical studies revealed absence of significant changes. Sulbactam-ampicillin combination being an effective, safe, and well tolerated antibiotic is welcomed addition to combat lower respiratory tract bacterial infections